Similarly, the peptide-Fc fusion L1-10 has been shown to block Ang-2 from binding the Tie2 receptor, which also decreases angiogenesis and tumor growth in both prostate cancer (Morrissey et al., 2010) and gliomas (Villeneuve et al., 2008). Here, ANGPT2 is linked to prostate carcinoma.